ISPOR - PBI7 Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany

PBI7 Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany

Abstract

Authors

J. Porter P. Stuart R. Bartsch A. Lebioda

Full Text Cite This Article

Back to Volume 24, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now